Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527265 · ClinicalTrials.gov registry record · Phase 2
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
A Phase 2 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02527265 is a Phase 2 study that has completed, run by Mannkind Corporation. The registered enrollment target is 30 participants.
The verdict
NCT02527265, a Phase 2 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objective: -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM). Secondary Objectives: * To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal. * To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4 to 17 years with T1DM.
Interventions
- BIOLOGICAL Afrezza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2020-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02527265
The ClinicalTrials.gov registry entry for NCT02527265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Afrezza is the first listed.
NCT02527265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02527265 about?
NCT02527265 is a clinical study titled "Afrezza Safety and Pharmacokinetics Study in Pediatric Patients". Primary Objective: -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM). Secondary Objectives: * To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal. * To assess pharmacokinetics (PK) followi...
What is the current status of trial NCT02527265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-09-28. Estimated completion is 2020-06-25.
What interventions are being tested in trial NCT02527265?
The interventions under investigation include: Afrezza (BIOLOGICAL).
Who is sponsoring clinical trial NCT02527265?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.